Modulation of AMPK Significantly Alters Uveal Melanoma Tumor Cell Viability

Ozge Deliktas1,2, M Emre Gedik3, Irem Koc1

  • 1Department of Ophthalmology, Hacettepe University Medical School, Ankara, Turkey.

Ophthalmic Research
|August 30, 2023
PubMed
Abstract

Insights

Targeting the Adenosine monophosphate-activated protein kinase (AMPK) pathway shows promise for treating uveal melanoma (UM). Activating AMPK reduced UM cell viability, while inhibiting it proved potent against UM cells in vitro.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Uveal melanoma (UM) exhibits poor response to current therapies.
  • Adenosine monophosphate-activated protein kinase (AMPK) is crucial for cell growth and survival.
  • Targeting the AMPK pathway presents a novel therapeutic strategy for UM.

Purpose of the Study:

  • To investigate the effects of modulating the AMPK pathway on UM cells.
  • To explore AMPK as a potential therapeutic target for uveal melanoma.

Main Methods:

  • In silico analyses (KEGG, GSEA) to compare UM and normal melanocytes.
  • In vitro assays (XTT) to assess cell viability and proliferation.
  • Treatment of UM cell lines with an AMPK activator (A-769662) and an inhibitor (dorsomorphin).

Main Results:

  • AMPK signaling pathway genes were differentially regulated in UM.
  • AMPK activation by A-769662 decreased UM cell viability in a dose-dependent manner.
  • AMPK inhibition by dorsomorphin potently reduced UM cell viability, with significant effects at low doses.

Conclusions:

  • AMPK's role in cancer is context-dependent.
  • Modulating the AMPK pathway offers a new therapeutic perspective for UM.
  • Targeting AMPK may lead to novel treatment approaches to improve UM survival.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K